[The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy]

M L Gershanovich; A Iu Zaritskiĭ; N V Medvedeva; K M Abdulkadyrov; I G Samuskevich; I A Beresneva

[The use of fludarabine phosphate (Fludara) to treat chronic B-cell lymphocytic leukemia and non-Hodgkin's lymphoma resistant to standard chemotherapy]

Vopr Onkol. 1998;44(6):696-700.

[Article in Russian]

Authors

M L Gershanovich¹, A Iu Zaritskiĭ, N V Medvedeva, K M Abdulkadyrov, I G Samuskevich, I A Beresneva

Affiliation

¹ Prof. N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St.Petersburg.

PMID: 10087967

Abstract

Following monochemotherapy with fludarabin phosphate (fludara), complete (18%), and partial remission (27%) with stabilization (45%) was recorded in patients with B-cell chronic lymphocytic leukemia, most of whom were resistant to alkylating cytostatic drugs and their combinations containing anthracyclines. Long-term remission was registered in patients with low and moderate grade non-Hodgkin's lymphoma, resistant to standard cytostatic treatment, due to the therapeutic synergism of fludara and cytosinarabinoside (FAVAMP).

Publication types

Clinical Trial
English Abstract

MeSH terms

Adult
Aged
Antimetabolites, Antineoplastic / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Drug Resistance, Neoplasm
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Lymphoma, Non-Hodgkin / drug therapy*
Male
Middle Aged
Treatment Outcome
Vidarabine Phosphate / analogs & derivatives*
Vidarabine Phosphate / therapeutic use

Substances

Antimetabolites, Antineoplastic
Vidarabine Phosphate
fludarabine phosphate